Euclidean Capital LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Euclidean Capital LLC reported 10 stock positions worth $238.0 million. Its top holding was Vanguard Ftse All-World Ex-U (VEU) at 77.3% of the portfolio, followed by iShares MSCI India ETF (INDA, 8.1%) and Oric Pharmaceuticals (ORIC, 5.0%). Compared with Q2 2025, it added to 1 and reduced 1. The biggest buy was Vanguard Ftse All-World Ex-U (VEU, shares +20%) and the biggest sale iShares MSCI India ETF (INDA, shares −85%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001825034
- Portfolio Value
- $238.0M (Q3 2025)
- SEC Filing
- 0001012975-25-000761 ↗ filed Nov 14, 2025
Holdings Value
Holdings 10 stocks · $238.0M
| VEU Vanguard Ftse All-World Ex-U | 77.31% | 2,578,184 | $184.0M | Add +20.3% |
| INDA iShares MSCI India ETF | 8.08% | 369,600 | $19.2M | Reduce -84.8% |
| ORIC Oric Pharmaceuticals Inc. | 4.99% | 989,410 | $11.9M | No change |
| FHTX Foghorn Therapeutics Inc. | 3.23% | 1,573,761 | $7.7M | No change |
| ALEC Alector Inc. | 1.63% | 1,307,858 | $3.9M | No change |
| PMVP PMV Pharmaceuticals Inc. | 1.55% | 2,627,643 | $3.7M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 1.15% | 4,104 | $2.7M | No change |
| RAPT Rapt Therapeutics Inc. | 0.89% | 82,234 | $2.1M | No change |
| TNYA Tenaya Therapeutics Inc. | 0.69% | 1,015,705 | $1.6M | No change |
| SRZN Surrozen Inc. | 0.47% | 87,696 | $1.1M | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $3K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 170,833 | $3K | No change |
Total filed on the 13F, all lines: $238.0M.
Portfolio Sells Q2 2025 → Q3 2025
| INDA iShares MSCI India ETF | Reduce -84.8% | 8.08% | −36.08 |
Portfolio Buys Q2 2025 → Q3 2025
| VEU Vanguard Ftse All-World Ex-U | Add +20.3% | 77.31% | +30.20 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $439.8M | VEU, VTV, INDA, ORIC, TMS |
| Q1 2026 | 9 | $392.3M | VEU, VTV, INDA, ORIC, FHTX |
| Q4 2025 | 11 | $369.4M | VEU, VTV, INDA, FHTX, ORIC |
| Q3 2025 | 10 | $238.0M | VEU, INDA, ORIC, FHTX, ALEC |
| Q2 2025 | 10 | $305.7M | VEU, INDA, ORIC, FHTX, PMVP |
| Q1 2025 | 10 | $266.1M | INDA, VEU, FHTX, ORIC, PMVP |
| Q4 2024 | 10 | $736.7M | SPY, INDA, VEU, ORIC, FHTX |
| Q3 2024 | 11 | $906.8M | SPY, INDA, VEU, FHTX, ORIC |
| Q2 2024 | 10 | $795.8M | SPY, INDA, FHTX, ORIC, ALEC |
| Q1 2024 | 12 | $780.0M | SPY, INDA, GLD, ORIC, FHTX |